The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will be up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,568
500 mcg, once daily, oral administration in the morning
once daily
Altana Pharma/Nycomed Investigational Site
Bayou La Batre, Alabama, United States
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama, United States
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama, United States
Altana Pharma/Nycomed Investigational Site
Huntsville, Alabama, United States
Altana Pharma/Nycomed Investigational Site
Bullhead City, Arizona, United States
Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]
Time frame: Change from baseline over 52 weeks of treatment
COPD Exacerbation Rate (Moderate or Severe)
Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\].
Time frame: 52 weeks treatment period
Post-bronchodilator FEV1 [L]
Mean change from baseline during the treatment period in post-bronchodilator FEV1 \[L\]
Time frame: Change from baseline over 52 weeks of treatment
Time to Mortality Due to Any Reason
Time frame: 52 weeks treatment period
Natural Log-transformed C-reactive Protein (CRP)
Mean change from baseline to the last post randomization measurement in natural log-transformed CRP
Time frame: Change from baseline to last post randomization measurement (52 weeks)
Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period
The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.
Time frame: Change from baseline over 52 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Altana Pharma/Nycomed Investigational Site
Phoenix, Arizona, United States
Altana Pharma/Nycomed Investigational Site
Phoenix, Arizona, United States
Altana Pharma/Nycomed Investigational Site
Fort Smith, Arkansas, United States
Altana Pharma/Nycomed Investigational Site
Little Rock, Arkansas, United States
Altana Pharma/Nycomed Investigational Site
Anaheim, California, United States
...and 277 more locations